로딩 중…
StockDiggingStockDigging

NanoenTek,Inc.

039860· KOSDAQ
₩4,030-4.50%
2026-06-19

Price Chart

NanoenTek,Inc.+11.02%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap153.52B KRW
Revenue40.66B KRW
Net Income2.65B KRW
Total Assets100.68B KRW
Net Assets92.04B KRW
Employees138
Value
P/E57.87x
P/B1.67x
PEG0.20x
P/S3.78x
EV/EBITDA120.79x
FCF Yield0.76%
Profitability
ROE2.88%
ROA2.64%
Op. Margin2.88%
Revenue Growth31.74%
Earnings Growth287.02%
Financial Health
Debt Ratio109.38%
FCF1.16B KRW
Cash12.30B KRW
Current Ratio10.44x
Net Debt/EBITDA-10.52x
Performance
1Y Return11.02%
1M Return-21.14%
From 52W High-57.08%
1Y MDD-47.46%
Trading
Volume266,431 shares
Foreign Own.1.25%
Per Share
EPS76 KRW
BPS2,432 KRW

Company Info

CEO 정찬일
Employees 138
Founded 1987
HQ 서울특별시 구로구, KR

NanoEnTek, established in 1987 as an information security business and rebranded in 2006, is headquartered in Guro-gu, Seoul. The company, slated to become a subsidiary of AAI Healthcare in 2025, specializes in Lab-on-a-chip based in-vitro diagnostic devices and immunodiagnostic systems. Its FREND System has received FDA approval and is stably supplied in North America. Utilizing Bio-MEMS and microfluidic technology, NanoEnTek conducts precise clinical tests, holding 108 registrations and expanding its business globally.